Gapping up
In reaction to strong earnings/guidance:
- N/A.
Other news:
- MGI +141.4% (on strategic agreement news with Ripple, a provider of enterprise blockchain solutions for global payments; Includes $30 million equity investment in MoneyGram)
- BYND +16% (continued strength; short squeeze)
- PHAS +12.5% (announces "positive preliminary results" from its Phase 2a clinical trial for PB2452)
- EIGR +9.6% (receives Breakthrough Therapy Designation from FDA for avexitide for the treatment of post-bariatric hypoglycemia)
- ARQL +2.6% (continued strength - was up 17% on the day)
- ILMN +1.8% (wins infringement suit against Ariosa Diagnostics; intends to seek all remedies for infringment)
- FB +1.6% (Facebook in 2020 will open a new subsidiary called Calibra; first product will be a new digital wallet for a new digital currency)
- AZN +1.6% (AstraZeneca & Merck (MRK) announce that the European Commission has approved Lynparza as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer)
- NVO +1.4% (confirms FDA approval of expanded indication for Victoza)
- SNY +1.2% (Sanofi and Google (GOOG) will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies)
- SCPL +0.9% (10% owner Park West bought ~330K shares worth ~$4.4 mln )
- HSY +0.9% (following CEO Michelle Buck CNBC interview)
- MRK +0.8% (FDA approves KEYTRUDA as monotherapy for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy)
- GE +0.7% (General Electric Aviation Unit: IndiGo places $20 bln LEAP order)
- SNV +0.6% (increases prior $400 mln share repurchase authorization to $725 mln)
Analyst comments:
- SPWR +5.8% (upgraded to Buy from Neutral at Goldman)
- RUN +4.4% (upgraded to Buy from Neutral at Goldman)
- TDS +4.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- TWLO +2.3% (initiated with a Buy at Needham)
- PINS +2% (initiated with Outperform rating and $33 tgt at Wedbush)
- SEDG +1.6% (upgraded to Neutral from Sell at Goldman)